| Design and evaluation of novel albumin-binding folate radioconjugates: systematic approach of varying the linker entities
Benešová, M., Guzik, P., Deberle, L. M., Busslinger, S. D., Landolt, T., Schibli, R., & Müller, C. (2022). Design and evaluation of novel albumin-binding folate radioconjugates: systematic approach of varying the linker entities. Molecular Pharmaceutics, 19, 963-973. https://doi.org/10.1021/acs.molpharmaceut.1c00932 |
| Combination of terbium-161 with somatostatin receptor antagonists - a potential paradigm shift for the treatment of neuroendocrine neoplasms
Borgna, F., Haller, S., Monné Rodriguez, J. M., Ginj, M., Grundler, P. V., Zeevaart, J. R., … Müller, C. (2022). Combination of terbium-161 with somatostatin receptor antagonists - a potential paradigm shift for the treatment of neuroendocrine neoplasms. European Journal of Nuclear Medicine and Molecular Imaging, 49, 1113-1126. https://doi.org/10.1007/s00259-021-05564-0 |
| Simultaneous visualization of <sup>161</sup>Tb-and <sup>177</sup>Lu-labeled somatostatin analogues using dual-isotope SPECT imaging
Borgna, F., Barritt, P., Grundler, P. V., Talip, Z., Cohrs, S., Zeevaart, J. R., … Müller, C. (2021). Simultaneous visualization of 161Tb-and 177Lu-labeled somatostatin analogues using dual-isotope SPECT imaging. Pharmaceutics, 13(4), 536 (13 pp.). https://doi.org/10.3390/pharmaceutics13040536 |
| Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates - new perspectives for folate receptor-targeted radionuclide therapy
Guzik, P., Benešová, M., Ratz, M., Monné Rodríguez, J. M., Deberle, L. M., Schibli, R., & Müller, C. (2021). Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates - new perspectives for folate receptor-targeted radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 48, 972-983. https://doi.org/10.1007/s00259-020-04980-y |
| Succinylated gelatin improves the theranostic potential of radiolabeled exendin-4 in insulinoma patients
Buitinga, M., Jansen, T., van der Kroon, I., Woliner-van der Weg, W., Boss, M., Janssen, M., … Gotthardt, M. (2019). Succinylated gelatin improves the theranostic potential of radiolabeled exendin-4 in insulinoma patients. Journal of Nuclear Medicine, 60(6), 812-816. https://doi.org/10.2967/jnumed.118.219980 |
| Therapeutic potential of <sup>47</sup>Sc in comparison to <sup>177</sup>Lu and <sup>90</sup>Y: preclinical investigations
Siwowska, K., Guzik, P., Domnanich, K. A., Monné Rodríguez, J. M., Bernhardt, P., Ponsard, B., … Müller, C. (2019). Therapeutic potential of 47Sc in comparison to 177Lu and 90Y: preclinical investigations. Pharmaceutics, 11(8), 424 (13 pp.). https://doi.org/10.3390/pharmaceutics11080424 |
| Albumin-binding PSMA ligands: optimization of the tissue distribution profile
Benešová, M., Umbricht, C. A., Schibli, R., & Müller, C. (2018). Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Molecular Pharmaceutics, 15(3), 934-946. https://doi.org/10.1021/acs.molpharmaceut.7b00877 |
| Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy
Umbricht, C. A., Benešová, M., Schibli, R., & Müller, C. (2018). Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Molecular Pharmaceutics, 15(6), 2297-2306. https://doi.org/10.1021/acs.molpharmaceut.8b00152 |
| Therapeutic radiometals beyond <sup>177</sup>Lu and <sup>90</sup>Y: production and application of promising α-particle, β<sup>–</sup>-particle, and Auger electron emitters
Müller, C., van der Meulen, N. P., Benešová, M., & Schibli, R. (2017). Therapeutic radiometals beyond 177Lu and 90Y: production and application of promising α-particle, β–-particle, and Auger electron emitters. Journal of Nuclear Medicine, 58(Suppl. 2), 91S-96S. https://doi.org/10.2967/jnumed.116.186825 |
| Preclinical comparison of albumin-binding radiofolates: impact of linker entities on the in vitro and in vivo properties
Siwowska, K., Haller, S., Bortoli, F., Benešová, M., Groehn, V., Bernhardt, P., … Müller, C. (2017). Preclinical comparison of albumin-binding radiofolates: impact of linker entities on the in vitro and in vivo properties. Molecular Pharmaceutics, 14(2), 523-532. https://doi.org/10.1021/acs.molpharmaceut.6b01010 |
| Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of <sup>161</sup>Tb-folate and <sup>177</sup>Lu-folate
Haller, S., Pellegrini, G., Vermeulen, C., van der Meulen, N. P., Köster, U., Bernhardt, P., … Müller, C. (2016). Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate. EJNMMI Research, 6(1), 13 (11 pp.). https://doi.org/10.1186/s13550-016-0171-1 |
| Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy
Haller, S., Reber, J., Brandt, S., Bernhardt, P., Groehn, V., Schibli, R., & Müller, C. (2015). Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy. Nuclear Medicine and Biology, 42(10), 770-779. https://doi.org/10.1016/j.nucmedbio.2015.06.006 |
| Folate receptor targeted alpha-therapy using terbium-149
Müller, C., Reber, J., Haller, S., Dorrer, H., Köster, U., Johnston, K., … Schibli, R. (2014). Folate receptor targeted alpha-therapy using terbium-149. Pharmaceuticals, 7(3), 353-365. https://doi.org/10.3390/ph7030353 |
| Promising prospects for <sup>44</sup>Sc-/<sup>47</sup>Sc-based theragnostics: application of <sup>47</sup>Sc for radionuclide tumor therapy in mice
Müller, C., Bunka, M., Haller, S., Köster, U., Groehn, V., Bernhardt, P., … Schibli, R. (2014). Promising prospects for 44Sc-/47Sc-based theragnostics: application of 47Sc for radionuclide tumor therapy in mice. Journal of Nuclear Medicine, 55(10), 1658-1664. https://doi.org/10.2967/jnumed.114.141614 |
| DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted <sup>177</sup>Lu-radionuclide tumor therapy in mice
Müller, C., Struthers, H., Winiger, C., Zhernosekov, K., & Schibli, R. (2013). DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice. Journal of Nuclear Medicine, 54(1), 124-131. https://doi.org/10.2967/jnumed.112.107235 |
| Prospects in folate receptor-targeted radionuclide therapy
Müller, C., & Schibli, R. (2013). Prospects in folate receptor-targeted radionuclide therapy. Frontiers in Oncology, 3, 249 (10 pp.). https://doi.org/10.3389/fonc.2013.00249 |
| PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with <sup>177</sup>Lu-DOTA-bombesin analogues
Däpp, S., Müller, C., Garayoa, E. G., Bläuenstein, P., Maes, V., Brans, L., … Schibli, R. (2012). PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues. EJNMMI Research, 2(1), 24 (12 pp.). https://doi.org/10.1186/2191-219X-2-24 |
| A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β<sup>−</sup>-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative
Müller, C., Zhernosekov, K., Köster, U., Johnston, K., Dorrer, H., Hohn, A., … Schibli, R. (2012). A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β−-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. Journal of Nuclear Medicine, 53(12), 1951-1959. https://doi.org/10.2967/jnumed.112.107540 |
| Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast
Reber, J., Struthers, H., Betzel, T., Hohn, A., Schibli, R., & Müller, C. (2012). Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast. Molecular Pharmaceutics, 9(5), 1213-1221. https://doi.org/10.1021/mp200511t |
| The low-energy β<sup>-</sup> and electron emitter <sup>161</sup>Tb as an alternative to <sup>177</sup>Lu for targeted radionuclide therapy
Lehenberger, S., Barkhausen, C., Cohrs, S., Fischer, E., Grünberg, J., Hohn, A., … Zhernosekov, K. (2011). The low-energy β- and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy. Nuclear Medicine and Biology, 38(6), 917-924. https://doi.org/10.1016/j.nucmedbio.2011.02.007 |
